Placing and Subscription

Ethtry PLC

23 October 2026

 

 23/10/2026

ETHTRY PLC

("Ethtry" or the "Company")

Placing and Subscription

Ethtry Plc (AQSE: ETHY), is pleased to announce it has raised gross proceeds of £210,000 via a direct subscription with the Company and a placing via its broker AlbR Capital Limited (together the "Fundraise"). The Fundraise involves the issue of 139,999,997 new ordinary shares ("Fundraising Shares") at a price of £0.0015 per share (the "Issue Price") and investors will receive one warrant (“Investor Warrant”) for every one new ordinary share, exercisable at 0.15p and subject to the terms of the warrant deed. The Fundraise is conditional on the admission of the Fundraising Shares to trading on the Aquis Stock Exchange (“Admission”). 

Placing and Subscription

AlbR Capital Limited ("AlbR"), as agent for the Company, has conditionally raised approximately £172,500.00 (before expenses) through a placing of 114,999,998 ordinary shares and £37,500.00 through a subscription for 24,999,999 ordinary shares, at the Issue Price. The Issue Price represents a discount of approximately 11.8% per cent. to the mid-market closing price of £.0017 per ordinary share on the close of business of 22 October 2026.

The subscription includes the participation through capitalisation of directors’ fees on the following basis; Mike Murphy will be investing £4,167.00 for 2,778,000 ordinary shares, Steve Winfield will be investing £4,167.00 for 2,778,000 ordinary shares and David Levis will be investing £4,166.00 for 2,777,333 ordinary shares.

 Following the Fundraise, the Directors will have the following shareholdings:

Director	No. shares	% of issued share capital
Mike Murphy	105,543,924	4.31%
Steve Winfield	2,778,000	0.11%
David Levis	14,614,270	0.60%

Investor Warrants

Participants in the Fundraising will receive one Investor Warrant for every one Fundraising Share. The 139,999,997 Investor Warrants will be valid for twelve months from the date of Admission with an exercise price of £0.0015.  

The proceeds of the placing and subscription will be used to strengthen the Company's balance sheet and provide working capital.

Total Voting Rights

The Fundraising Shares will rank pari passu with the existing ordinary shares of £0.00002 each in all respects. Application will be made for the Fundraising Shares to be admitted to trading on the Aquis Growth Market and Admission is expected to occur on 29 October 2026.

Following Admission, the Company will have 2,450,106,267 ordinary shares in issue, each with one voting right. The Company does not hold any shares in treasury and therefore the total number of voting rights in the Company will be 2,450,106,267 on Admission.

Related Party Transactions

The participation of the Directors in the Fundraise constitutes a related party transaction under Rule 4.6 of the Aquis Growth Market Rulebook (the "Transaction"). As all of the Company's directors are participating in the Fundraise, there are no directors independent of the Transaction to confirm that the terms of the Transaction are fair and reasonable insofar as shareholders are concerned as is required pursuant to Rule 4.6.

Consequently, AlbR Capital, the Company's Aquis Corporate Adviser confirms that it believes that the terms of the Transaction are fair and reasonable insofar as shareholders are concerned.

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended.

THE DIRECTORS OF THE COMPANY TAKE RESPONSIBILITY FOR THE CONTENTS OF THIS ANNOUNCEMENT

Enquiries

Company:

Mike Murphy, Director

David Levis, Non-Executive Director
Steve Winfield, Director

AQSE Growth Market Corporate Adviser

AlbR Capital (Aquis Corporate Adviser)

David Coffman

Tel: [phone]

 

END